Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

University of Macau | Macau

Dr. Xiaowen Mao, M.D., Ph.D., is an Assistant Professor at the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, where she leads translational research on cancer biology, immunotherapy, and tumor microenvironment modulation. She earned her Ph.D. in Biomedical Sciences from the University of Hong Kong and her B.Sc. in Clinical Medicine from Shanghai Jiao Tong University, China. Her research focuses on extracellular vesicles, immune homeostasis, metabolic reprogramming in tumors, and hepatocellular carcinoma metastasis, integrating molecular, cellular, and translational approaches. Dr. Xiaowen Mao has led several high-impact projects as principal investigator, funded by the Health and Medical Research Fund, National Natural Science Foundation Young Scientist Fund, and FDCT Innovation and Technology Promotion. Her significant contributions include the development of broadly potent neutralizing antibodies targeting Nidogen 1 to inhibit tumor growth, elucidation of extracellular vesicle-mediated metabolic reprogramming in tumors, and advances in dendritic cell vaccine strategies. She holds a U.S. patent on Nidogen 1 as a diagnostic and therapeutic target for hepatocellular carcinoma, serves as Guest Editor for Frontiers in Endocrinology, and is an ad-hoc reviewer for multiple high-impact journals. According to Scopus, she has 31 publications, 1,114 citations by 1,010 documents, and an h-index of 20. Dr. Xiaowen Mao’s work bridges fundamental research and clinical translation, delivering innovative therapies and advancing precision medicine in oncology, while demonstrating a profound impact on cancer biology, immunotherapy, and translational research.

Profile: Scopus

Featured Publications

  • Xue, T. M., Yeung, C. L. S., Mao, X. W., Tey, S. K., Lo, K. W., Tang, H. N., Yun, J. P., & Yam, J. W. P. (2025). Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. Journal of Translational Internal Medicine. https://doi.org/10.1515/jtim-2025-0008

  • Xia, L., Li, C. G., Zhao, J., Sun, Q. C., & Mao, X. W.* (2025). Rebalancing immune homeostasis in combating disease: The impact of medicine food homology plants and gut microbiome. Phytomedicine, 136, 156150. https://doi.org/10.1016/j.phymed.2025.156150

  • Chen, Z., Yam, J. W. P., & Mao, X. W.* (2024). The multifaceted roles of small extracellular vesicles in metabolic reprogramming in the tumor microenvironments. Proteomics, e2300021. https://doi.org/10.1002/pmic.202300021

  • Lee, K. W., Yam, J. W. P., & Mao, X. W.* (2023). Dendritic cell vaccines: A shift from conventional approach to new generations. Cells, 12(2147). https://doi.org/10.3390/cells12172147

  • Li, S., Delvecchio, M., Ramkumar, K., Mao, X. W., Sun, X. D., & Guo, S. Z. (2023). Editorial: Clinical and genetic determinants of diabetes and complications. Frontiers in Endocrinology.

Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Mr. Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Chaoyang Hospital | China

Mr. Zhechun Wu is a resident physician in the Department of Urology at Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, who has established himself as an emerging clinician–scientist combining medical training with impactful research. He earned his Bachelor of Science degree from Capital Medical University and is currently advancing his clinical expertise through residency while contributing to translational oncology research. His work is focused on prostate cancer, with particular emphasis on identifying therapeutic targets that regulate tumor immunity, a critical area for developing next-generation treatment strategies. Mr. Zhechun Wu has published in reputable international journals, including a recent article in Investigational New Drugs that explored drug targets modulating tumor immune response, a study that has already been cited in related scholarly work, reflecting its scientific significance. His projects are supported by competitive funding from the National Natural Science Foundation of China  and the Beijing Natural Science Foundation, highlighting his ability to secure prestigious grants and deliver research with clinical and academic value. Alongside research, his clinical practice in urology, oncology, and kidney transplantation strengthens his understanding of patient-centered challenges, allowing him to align laboratory findings with real-world medical needs. This dual role as physician and researcher equips him to contribute to both advancing cancer therapeutics and improving clinical outcomes, establishing a foundation for future leadership in medical innovation and academic research.

Profile: ORCID

Featured Publications

Zhang, Y., Qiu, X., Wu, Z., Li, Y., Shen, X., Wu, J., Cao, P., Sun, Z., & Wang, W. (2025). Comprehensive analysis of the association between volatile organic compound pollutants and chronic kidney disease in hypertensive populations: Insights from multi-omics approaches and identification of potential therapeutic targets. Environmental Research, 121966.

Wu, Z., Li, S., Li, Y., Wang, Z., & Wang, W. (2025). Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity. Discover Oncology, 16, 98.

Wu, Z. (2025). Higher sexual frequency correlated with lowered PSA complex levels in U.S. men over 40 and without prostate conditions: A nationwide cross-sectional study. The Journal of Sexual Medicine.

Yan Bai | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Yan Bai | Medicine and Health Sciences | Best Researcher Award

Yunnan University | China

Dr. Yan Bai is a highly accomplished postdoctoral researcher at the State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan and the Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China. She earned her PhD in Cell Biology from Yunnan University, MSc in Pharmacology from the Chinese PLA Medical Academy, and BSc in Pharmacy from Dali University, establishing a strong interdisciplinary foundation spanning pharmacology, microbiology, and cellular biology. Prior to her current role, she conducted research at the Chinese PLA General Hospital, focusing on combination therapies against multidrug-resistant bacteria. Her research primarily investigates mitochondrial homeostasis, tumor biology, and the molecular mechanisms underlying mitochondrial genetic diseases, with particular attention to mitochondria-associated condensates (MATOs) as regulators of protein translation and mitochondrial integrity. Dr. Yan Bai has led and contributed to several major research projects, including grants from the National Natural Science Foundation of China, the National Basic Research Program, and Yunnan Province Science and Technology initiatives. Her work has resulted in high-impact publications in journals such as Nature Aging (2025), Sci China Life Sci (2025), EMBO J (2024), and Biophys Rep (2024). According to Scopus, she has authored 10 publications, cited 177 times across 169 documents, with an h-index of 6, demonstrating both productivity and influence in her field. Through her interdisciplinary collaborations, innovative experimental approaches, and groundbreaking findings on mitochondrial regulation and aging, Dr. Yan Bai has made significant contributions to biomedical science, advancing understanding of mitochondrial biology, disease mechanisms, and translational biomedical applications.

Profile: Scopus

Featured Publications

Bai, Y., Ma, T., Zhao, S., Li, S., Wang, X., Li, J., Sun, W., Yang, Y., Liu, F., Shan, Q., Qin, Z., Liu, N., Zhang, J., Tian, F., Duan, M., Chen, S., Lai, F., Chen, Q., Wu, X., & Yang, C. (2025). Mitochondria-associated condensates maintain mitochondrial homeostasis and promote lifespan. Nature Aging.

Hao, Q., Bai, Y., Guan, R., Dong, R., Bai, W., Hamdy, H., Wang, L., Meng, M., Sun, Y., Shen, J., & Sun, J. (2025). VPS35/Retromer-dependent MT1-MMP regulation confers melanoma metastasis. Science China Life Sciences, 68(7), 1996–2009.

Hao, Q., Dong, R., Bai, W., Chang, D., Yao, X., Zhang, Y., Xu, H., Li, H., Kui, X., Wang, F., Wang, Y., Wang, C., Lei, Y., Chen, Y., Shen, J., Sang, L., Bai, Y., & Sun, J. (2024). Screening for metastasis-related genes in mouse melanoma cells through sequential tail vein injection. Biophysical Reports, 10(1), 15–21.

Liu, F., Li, T., Gong, H., Tian, F., Bai, Y., Wang, H., Yang, C., Li, Y., Guo, F., Liu, S., & Chen, Q. (2024). Structural insights into the molecular effects of the anthelmintics monepantel and betaine on the Caenorhabditis elegans acetylcholine receptor ACR-23. EMBO Journal, 43(17), 3787–3806.

Wang, T., Zhou, X., Bai, Y., Zhang, L., Li, L., & Wu, C. (2018). Antiepileptic effect of uridine may be caused by regulating dopamine release and receptor expression in corpus striatum. Brain Research, 1688, 47–53.

Bai, Y., Liu, B., Wang, T., Cai, Y., Liang, B., Wang, R., Liu, Y., & Wang, J. (2015). In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 59(3), 1466–1471.

Liu, B., Bai, Y., Liu, Y., Di, X., Zhang, X., Wang, R., & Wang, J. (2015). In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. Journal of Chemotherapy, 27(5), 271–276.

Shoukui Hu | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Shoukui Hu | Medicine and Health Sciences | Best Researcher Award

Zhengzhou Central Hospital Affiliated to Zhengzhou University | China

Dr. Shoukui Hu is a distinguished medical microbiologist and molecular biologist currently serving as the Director of the Clinical Laboratory and Blood Transfusion Department at Peking University Shougang Hospital. With over two decades of impactful work in pathogenic biology, Dr. Hu has been instrumental in advancing public health diagnostics and molecular epidemiology in China. His leadership and research contributions have strengthened clinical laboratory practices and disease surveillance.

Author Profile👤

ORCID

Scopus

Strengths for the Awards✨

Dr. Shoukui Hu brings over two decades of experience in pathogenic biology and molecular biology, having contributed significantly to public health and clinical research in China. He currently serves as the Director of the Clinical Laboratory and Blood Transfusion Department at Peking University Shougang Hospital, a role that highlights both his leadership capabilities and clinical expertise. His academic journey, culminating in a Ph.D. from the China CDC, laid a solid foundation for impactful research in infectious diseases, microbiology, and translational diagnostics.

A standout strength is his strong publication record, with at least nine peer-reviewed SCI-indexed articles published in the past five years alone—many as corresponding or first author. These papers cover emerging infectious pathogens such as Candida auris, Helicobacter pylori, Neisseria meningitidis, and Streptococcus pneumoniae, which are critical topics in global public health. His research has been published in high-impact Q1 and Q2 journals such as Gut Microbes, Helicobacter, BMC Genomics, and World Journal of Gastroenterology, demonstrating relevance, innovation, and scientific rigor.

Furthermore, Dr. Hu’s expertise in molecular diagnostics, particularly the development of biosensors and amplification techniques, shows clear translational value, directly impacting clinical diagnostics and public health surveillance systems. His dual expertise in research and hospital management positions him as a bridge between science and clinical application—an invaluable trait for advancing healthcare innovations.

🎓 Education

Dr. Hu began his academic journey with a BSc from Anhui Science and Technology University (1995–1999), followed by an MSc in Microbiology (2001–2004) jointly awarded by the National Institute for Communicable Disease Control and Prevention and Anhui Agricultural University. He then earned his Ph.D. in Pathogeny Biology (2009–2014) from the same institute under the China CDC, equipping him with a deep scientific foundation to drive impactful research.

🧪 Experience

Currently the Senior Technologist and Director at Peking University Shougang Hospital (since 2016), Dr. Hu has also held vital roles such as Postdoctoral Fellow in Molecular Epidemiology at the China CDC (2014–2016) and Associate Senior Technologist at Peking University International Hospital (2014). From 2004 to 2014, he served as Deputy Department Director of the Microbiology Lab at Anhui CDC, where he led several high-level surveillance and diagnostic programs across China.

🔬 Research Interests On Medicine and Health Sciences

Dr. Hu’s research passion lies at the intersection of pathogenic biology and molecular biology. He is particularly focused on Helicobacter pylori infections, gut microbiota, antimicrobial resistance, and the genomic characterization of emerging pathogens. His studies contribute valuable insight into immune mechanisms, pathogen identification, and microbiome-related diseases.

🏆 Awards

While specific awards are not listed in the provided CV, Dr. Hu’s consistent corresponding authorship and leadership in high-impact international publications indicate significant professional recognition. His role in directing laboratory operations at a top-tier hospital and publishing in top Q1 journals further reflects his prestige and contributions to global health science.

📚 Publications

Below are key publications from the past 5 years, with hyperlinks, journal names, years, and citation roles:

  1. Isolation of Fluconazole-Resistant South Asian Clade Candida auris in Beijing, China, American Journal of Tropical Medicine and Hygiene, 2025 – Corresponding Author

  2. Influence of Helicobacter pylori on composition and function of gastric microbiota in patients with chronic non-atrophic gastritis, Heliyon, 2024 – Corresponding Author

  3. The role of toll-like receptors in immune tolerance induced by Helicobacter pylori infection, Helicobacter, 2023 – Corresponding Author

  4. Comparative analysis of the gut microbiota of wild adult rats from nine district areas in Hainan, China, World Journal of Gastroenterology, 2023 – Corresponding Author

  5. Ultra-efficient multiple cross displacement amplification-lateral flow biosensor for serogroup identification of prevalent Neisseria meningitidis, Analytical Biochemistry, 2022 – Corresponding Author

  6. Simultaneous detection of Streptococcus pneumoniae… using multiple cross displacement amplification, FEMS Microbiology Letters, 2021 – Corresponding Author

  7. Hemolysin BL from Bacillus toyonensis BV-17 induces antitumor activity both in vitro and in vivo, Gut Microbes, 2020 – Co-First Author

  8. Genomic analysis of Helicobacter himalayensis sp. nov. isolated from Marmota himalayana, BMC Genomics, 2020 – First Author

  9. Alteration of gut microbiota in type 2 diabetes complicated with cholelithiasis patients, Chinese Medical Journal, 2022 – Corresponding Author

✅ Conclusion

🎖️ Dr. Shoukui Hu is a pioneering clinical researcher and laboratory expert whose work spans epidemiological surveillance, diagnostic innovation, and microbiome science. With a sustained record of leadership, publication, and mentorship, he exemplifies the qualities of a Best Researcher Award nominee. His scholarly output and translational impact make him a key contributor to advancing infectious disease control and laboratory science in China and beyond.

Zhengfeng Jia | Medicine | Excellence in Research

Published on by Forensic Scientist

Prof. Dr. Zhengfeng Jia | Medicine | Excellence in Research

Fourth medical PLA general hospital | China

Dr. Zhengfeng Jia is a researcher in orthopedic biomechanics, focusing on distal humerus fractures, musculoskeletal dynamics, and finite element analysis. Affiliated with the Chinese PLA General Hospital and the National Clinical Research Center for Orthopedics, his work bridges computational modeling and clinical applications to optimize fracture fixation and rehabilitation strategies.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Innovative Methodology

    • The study integrates musculoskeletal dynamics (AnyBody software) with finite element analysis (Abaqus) to simulate real-world biomechanical conditions, overcoming the limitations of traditional static models.

    • The AnyBody-Abaqus coupling technique provides dynamic loading conditions, capturing muscle forces and joint reactions during elbow flexion/extension, which is rare in orthopedic biomechanics research.

  2. Clinical Relevance

    • Addresses a critical gap in distal humerus fracture management by quantifying “safe activity windows” for postoperative rehabilitation (e.g., ≤80° flexion for parallel plates, ≤30° for vertical plates).

    • Findings directly inform surgical decisions (e.g., plate configuration) and rehabilitation protocols to reduce complications like non-union.

  3. Rigorous Validation

    • Validates muscle forces using electromyography (EMG) literature and mesh convergence studies to ensure computational accuracy (<5% error).

    • Anatomical accuracy is confirmed via statistical shape modeling (SSM) and iterative closest point (ICP) algorithms (<1.2 mm error).

  4. High-Impact Results

    • Demonstrates that parallel plates outperform vertical plates in maintaining interfragmentary motion (IFM) within the healing threshold (0.06–0.20 mm).

    • Identifies stress migration paths in the humerus, correlating with anatomical weak zones (e.g., lateral condyle).

  5. Interdisciplinary Approach

    • Combines orthopedic surgery, biomechanics, and computational modeling, aligning with the trend of “smart orthopedics.”

Education 🎓

  • PhD Candidate in Orthopedics, Graduate School of Medical School of Chinese PLA Hospital, Beijing (Current).

  • Research training in musculoskeletal dynamics, 3D modeling, and finite element analysis (FEA).

Experience 💼

  • Researcher at the Fourth Medical Center of Chinese PLA General Hospital, Beijing.

  • Specializes in digital orthopedic technologies, including AnyBody-Abaqus joint modeling and biomechanical simulations.

  • Collaborates on studies quantifying “safe activity windows” for postoperative rehabilitation.

Research Interests On Medicine 🔍

  • Biomechanics of distal humerus fractures.

  • Musculoskeletal dynamics and finite element analysis (FEA).

  • Optimization of internal fixation plates and rehabilitation protocols.

  • AI applications in orthopedic decision-making.

Awards & Nominations 🏆

  • National Clinical Research Center for Orthopedics Grant (2024) for data-driven ulnar prostheses research.

  • Ethical approval recipient (2024KY005-KS001) for studies on fracture healing biomechanics.

Publications 📚

  1. Jia, Z., Xu, C., Gao, W., et al. (2025). Evaluation of internal fixation stability of distal humerus C-type fractures based on musculoskeletal dynamics: Finite element analysis under dynamic loading. Journal of Orthopaedic Surgery and Research, *20*(475).

  2. Contributed to meta-analyses on continuous passive motion post-arthroplasty (J Orthop Surg Res, 2024).

Conclusion 🌟

Zhengfeng Jia’s multidisciplinary research quantifies biomechanical thresholds for fracture healing, emphasizing parallel plate configurations and 30–80° flexion safety windows. His integration of AnyBody-Abaqus modeling advances personalized rehabilitation strategies, with future aims to validate findings in clinical trials and AI-driven orthopedic solutions.

Xiaoling Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Anquan Shang | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Anquan Shang | Medicine | Best Researcher Award

The Second People’s Hospital of Lianyungang | China

Prof. Anquan Shang is a distinguished Associate Chief Laboratory Technician and Clinical Laboratory Physician with an H-index of 26. At the age of 39, he has made significant contributions to the field of clinical laboratory diagnostics. As a master’s supervisor, he plays a crucial role in mentoring future medical professionals. He is currently affiliated with Shanghai Jiao Tong University and has extensive experience in tumor marker research and clinical diagnostics.

Profile👤

ORCID

Google Scholar

Scopus

Strengths for the Awards✨

  • Strong Research Productivity 

    • H-index of 26, indicating high citation impact.
    • Over 70 SCI and core journal publications as first or corresponding author.
    • Multiple high-impact factor papers in oncology, microbiology, and immunology.

  • Impressive Funding & Grants 

    • Secured multiple national and provincial-level research grants.
    • Led and participated in 13+ major projects in oncology, infection, and precision diagnostics.

  • Leadership & Recognition 

    • Head of key clinical departments and training programs in prestigious hospitals.
    • Recognized in Shanghai and Jiangsu talent programs, highlighting academic excellence.

  • Significant Innovations & Impact 

    • Contributions to liquid biopsy, tumor biomarkers, and infection diagnostics.
    • 5+ patents, demonstrating translational research impact.

  • Professional Network & Influence 

    • Active in national and international research communities.
    • Reviewer and editor for multiple scientific journals.

🎓 Education

His academic journey began with a specialization in medical laboratory technology at Xiangfan Vocational and Technical College (2005-2008). He then pursued a bachelor’s degree in medical laboratory science at Jiangsu University (2011-2014), followed by a master’s degree in clinical laboratory diagnostics at Ningxia Medical University (2014-2017). He furthered his expertise with a Ph.D. in clinical laboratory diagnostics from Tongji University (2017-2020), establishing a strong foundation for his research career.

🏥 Experience

Currently, he is a postdoctoral researcher in clinical laboratory diagnostics at Ruijin Hospital, affiliated with Shanghai Jiao Tong University (2025-present), focusing on tumor biomarker research. Since 2023, he has led the Clinical Laboratory Medicine Department at Lianyungang Second People’s Hospital, a key clinical specialty in Jiangsu Province. Previously, he completed another postdoctoral fellowship at Tongji University (2020-2022), researching tumor microenvironment and biomarkers. His clinical experience spans roles as a laboratory technician at various hospitals between 2008 and 2014, steadily advancing to leadership positions.

🔬 Research Interests On Medicine

His research focuses on:

1️⃣ Tumor immunology 🧬

2️⃣ Infection microecology and immune microenvironment remodeling 🦠

3️⃣ Precision molecular diagnostics for chronic diseases 🏥

4️⃣ Liquid biopsy techniques for early disease detection 💉

🏆 Awards

He has received numerous prestigious awards, including the Yancheng City Natural Science Achievement Award (3 times), the Yancheng Medical New Technology Introduction Award (5 times), and the Huaihai Science and Technology Progress Award (2nd Prize, twice). From 2019-2022, he was consecutively recognized as an Outstanding Young Scientific Researcher by the Shanghai Medical Association Laboratory Medicine Branch.

📚 Publications

  • Title: Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis
    Authors: A Shang, C Gu, W Wang, X Wang, J Sun, B Zeng, C Chen, W Chang, …
    Publication Year: 2020
    Citations: 372

  • Title: Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
    Authors: A Shang, W Wang, C Gu, C Chen, B Zeng, Y Yang, P Ji, J Sun, J Wu, …
    Publication Year: 2019
    Citations: 147

  • Title: Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression
    Authors: A Shang, C Gu, C Zhou, Y Yang, C Chen, B Zeng, J Wu, W Lu, W Wang, …
    Publication Year: 2020
    Citations: 100

  • Title: Tumor microenvironment: lactic acid promotes tumor development
    Authors: Y Gao, H Zhou, G Liu, J Wu, Y Yuan, A Shang
    Publication Year: 2022
    Citations: 80

  • Title: Exosomal miR-183-5p promotes angiogenesis in colorectal cancer by regulation of FOXO1
    Authors: A Shang, X Wang, C Gu, W Liu, J Sun, B Zeng, C Chen, P Ji, J Wu, …
    Publication Year: 2020
    Citations: 77

  • Title: Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer
    Authors: AQ Shang, J Wu, F Bi, YJ Zhang, LR Xu, LL Li, FF Chen, WW Wang, …
    Publication Year: 2017
    Citations: 77

  • Title: Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p
    Authors: AQ Shang, WW Wang, YB Yang, CZ Gu, P Ji, C Chen, BJ Zeng, JL Wu, …
    Publication Year: 2019
    Citations: 70

  • Title: IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
    Authors: J Cui, J Tian, W Wang, T He, X Li, C Gu, L Wang, J Wu, A Shang
    Publication Year: 2021
    Citations: 62

  • Title: miR‐381‐3p restrains cervical cancer progression by downregulating FGF7
    Authors: A Shang, C Zhou, G Bian, W Chen, W Lu, W Wang, D Li
    Publication Year: 2019
    Citations: 62

  • Title: Vaginal microecological characteristics of women in different physiological and pathological period
    Authors: L Shen, W Zhang, Y Yuan, W Zhu, A Shang
    Publication Year: 2022
    Citations: 59

🔚 Conclusion

With a strong academic background, leadership in clinical laboratory medicine, and groundbreaking research in tumor immunology and molecular diagnostics, he continues to make significant contributions to medical science. His extensive experience, prestigious awards, and influential publications highlight his dedication to advancing clinical diagnostics and improving patient outcomes.

Qianghua Lv | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Qianghua Lv | Medicine | Best Researcher Award

Shandong Academy of Agricultural Sciences | China

Dr. Qianghua LV is an Associate Researcher at the Institute of Animal Science and Veterinary Medicine (IASVM), Shandong Academy of Agricultural Sciences (SAAS). He earned his Ph.D. in Veterinary Pharmacology under the mentorship of Prof. DENG Xuming at Jilin University in 2020. His research focuses on developing novel therapeutic strategies targeting bacterial virulence factors, including bacterial hemolysin, Type III Secretion System (T3SS), and Type IV Pili (TFP). His work contributes significantly to understanding anti-infective mechanisms and advancing new drug development against bacterial infections.

Profile👤

ORCID

Strengths for the Awards✨

  • High-Impact Research Focus – Dr. LV Qianghua’s work on anti-infection mechanisms and natural compound-based drug development aligns with global health priorities, particularly in combating superbacterial infections. His research on bacterial virulence factors like hemolysin, T3SS, and TFP contributes to the development of novel antimicrobial strategies.

  • Quality Publications in Reputable Journals – He has multiple first-author and co-first-author publications in high-impact journals, such as Journal of Cellular and Molecular Medicine and Applied Microbiology and Biotechnology. These papers focus on novel antibacterial mechanisms and natural product inhibitors, demonstrating both innovation and scientific rigor.

  • Translational Impact – His research not only advances basic microbiology but also holds significant translational potential in developing new antibacterial therapies, an area of urgent medical need due to rising antibiotic resistance.

  • Collaborative and Multi-Disciplinary Approach – His collaborations with researchers across multiple disciplines (pharmacology, microbiology, and veterinary medicine) enhance the applicability of his findings beyond veterinary science, benefiting both animal and human health.

  • Contribution to Veterinary Medicine – As an Associate Researcher at the IASVM, SAAS, Dr. LV contributes significantly to veterinary pharmacology, a field essential for both agricultural and public health. His work has implications for livestock disease management and food safety, making it highly relevant for both academia and industry.

🎓 Education

  • Ph.D. in Veterinary Pharmacology, Jilin University, 2020
    • Advisor: Prof. DENG Xuming
    • Research Focus: Anti-infection mechanisms of natural compounds targeting bacterial virulence factors

💼 Experience

  • Associate Researcher, IASVM, SAAS (2020–Present)
    • Conducting research on antibacterial strategies targeting virulence factors
    • Screening natural compounds for inhibitory effects on bacterial infections
    • Developing new therapeutic agents against superbacterial infections

🔬 Research Interests On Medicine

  • 🦠 Discovery and screening of novel targets and lead compounds against superb acterial infections
  • 💊 Synergistic antibacterial effects and mechanisms of natural compounds and antimicrobial agents

📚 Selected Publications

  • Title: Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium
    Authors: Lv Q(#), Chu X(#), Yao X, Ma K, Zhang Y*, Deng X*
    Publication Year: 2019
    Journal: Journal of Cellular and Molecular Medicine

  • Title: Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system
    Authors: Lv Q(#), Li S(#), Wei H, Wen Z, Wang Y, Tang T, Wang J, Xia L*, Deng X*
    Publication Year: 2020
    Journal: Applied Microbiology and Biotechnology

  • Title: Phloretin potentiates polymyxin E activity against Gram-negative bacteria
    Authors: Du R(#), Lv Q(#), Hu W, Hou X, Zhou Y, Deng X, Sun L, Li L, Deng Y, Wang J
    Publication Year: 2021
    Journal: Life Sciences

  • Title: Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection
    Authors: Zhou Y, Liu B, Chu X, Su J, Xu L, Li L, Deng X, Li D*, Lv Q*, Wang J*
    Publication Year: 2022
    Journal: Communications Biology

  • Title: Isoflavone glucoside genistin, an inhibitor targeting Sortase A and Listeriolysin O, attenuates the virulence of Listeria monocytogenes in vivo and in vitro
    Authors: Liu M(#), Lv Q(#), Xu J, Liu B, Zhou Y, Zhang S, Shen X, Wang L
    Publication Year: 2023
    Journal: Biochemical Pharmacology

🔚 Conclusion

Dr. LV Qianghua has dedicated his research to developing innovative antibacterial strategies, focusing on targeting bacterial virulence factors. His contributions in natural compound screening and new drug development have advanced the fight against superbacterial infections. With numerous impactful publications and ongoing research, he continues to make significant strides in veterinary medicine and pharmacology.

Guowei Zheng | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Guowei Zheng | Medicine | Best Researcher Award

Yunnan University of Chinese Medicine | China

Dr. Guowei Zheng is a distinguished professor at Yunnan University of Chinese Medicine, specializing in medicinal plant research. His work focuses on the collection, evaluation, and breeding of medicinal plant germplasm, as well as understanding plant responses to stress and exploring the biosynthetic pathways of medicinal ingredients in Chinese herbs. With extensive academic experience spanning over a decade, Dr. Zheng has made significant contributions to plant biology through multiomics approaches and phytochemical studies.

Profile👤

ORCID

Strengths for the Awards✨

  • Strong Research Output 📚

    • Dr. Zheng has published over 20 high-quality research papers in reputable journals, including BMC Plant Biology, Plant Diversity, PLoS ONE, and Phytochemistry.
    • His recent publications (2023–2025) demonstrate consistent research contributions, particularly in multi-omics, metabolomics, and medicinal plants.

  • Diverse Research Expertise 🔬

    • His work spans multiple critical areas, including medicinal plant breeding, stress response, and biosynthetic pathways of Chinese herbs.
    • His research on polyphyllin biosynthesis, glycerolipidome responses, and CO₂ elevation effects contributes to both fundamental science and applied plant biotechnology.

  • Academic and Professional Growth 📈

    • Rising from Assistant Professor (2010) to Full Professor (2021) at Yunnan University of Chinese Medicine.
    • Previous tenure at Kunming Institute of Botany, Chinese Academy of Sciences, a prestigious research institution.

🎓 Education

  • Ph.D. in Botany (2005–2010) – Kunming Institute of Botany, Chinese Academy of Sciences
  • Bachelor’s Degree in Biology (2001–2005) – Yunnan University

👨‍🏫 Experience

  • Professor (2021–Present) – Yunnan University of Chinese Medicine
  • Associate Professor (2018–2021) – Yunnan University of Chinese Medicine
  • Associate Professor (2016–2018) – Kunming Institute of Botany, Chinese Academy of Sciences
  • Assistant Professor (2010–2015) – Kunming Institute of Botany, Chinese Academy of Sciences

🔬 Research Interests On Medicine

  • 🌿 Medicinal Plant Germplasm – Collection, evaluation, and breeding of medicinal plant species
  • 💧 Plant Stress Response – Studying how medicinal plants adapt to environmental stressors
  • 🧪 Phytochemical Biosynthesis – Investigating synthesis pathways of medicinal compounds in Chinese herbs

🏆 Awards

(Please provide specific awards or recognitions received.)

📚 Publications

Dr. Zheng has published extensively in high-impact journals, contributing significantly to plant biology and phytochemistry.

  • Xu, P., Mi, Q., Zhang, X., Zhang, X., Yu, M., Gao, Y., Wan, X., Chen, Y., Li, Q., Chen, J., & Zheng, G. (2025). Dissection of transcriptome and metabolome insights into the polyphyllin biosynthesis in Paris. BMC Plant Biology, 25(1), 206.

  • Xu, P., Chen, J., Mi, Q., Li, W., Lu, Y., Luo, W., Yu, M., Zhang, X., Tu, Z., Xu, H., & Zheng, G. (2024). Metabolomics and transcriptomics profiling of three Paris species with varied polyphyllin compositions. Sci Data, 11(1), 1293.

  • Zheng, G., Li, W., Zhang, S., Mi, Q., Luo, W., Zhao, Y., Qin, X., Li, W., Pu, S., & Xu, F. (2023). Multiomics strategies for decoding seed dormancy breakdown in Paris polyphylla. BMC Plant Biology, 23(1), 247.

  • Li, W., Zhang, X., Pei, W., & Zheng, G. (2021). First Report of Root Rot Caused by Dactylonectria torresensis on Bletilla striata (Baiji) in Yunnan, China. Plant Disease, 0(0), PDIS-10-20-2166-PDN.

  • Liu, T., Chen, J., Xu, F., He, X., Yang, S., Zhu, Y., Li, W., & Zheng, G. (2020). Analysis of changes in the Panax notoginseng glycerolipidome in response to long-term chilling and heat. Plant Diversity, 42, 102-110.

  • Zheng, G., Cheng, J., & Li, W. (2020). Impacts of CO2 elevation on the physiology and seed quality of soybean. Plant Diversity, 42(1), 44-51.

  • Zheng, G., Luo, S., Li, S., Hua, J., Li, W., & Li, S. (2018). Specialized metabolites from Ageratina adenophora and their inhibitory activities against pathogenic fungi. Phytochemistry, 148, 57-62.

  • Zheng, G., & Li, W. (2017). Profiling membrane glycerolipids during gamma-ray-induced membrane injury. BMC Plant Biology, 17(1), 203.

  • Chen, J., Zheng, G., Zhang, Y., Aisa, H. A., & Hao, X. (2017). Phytotoxic Terpenoids from Ligularia cymbulifera Roots. Front Plant Sci, 7, 2033.

  • Zheng, G., Li, L., & Li, W. (2016). Glycerolipidome responses to freezing- and chilling-induced injuries: examples in Arabidopsis and rice. BMC Plant Biology, 16, 70.

  • Tang, T., Liu, P., Zheng, G., & Li, W. (2016). Two phases of response to long-term moderate heat: Variation in thermotolerance between Arabidopsis thaliana and its relative Arabis paniculata. Phytochemistry, 122, 81-90.

🔚 Conclusion

Dr. Guowei Zheng is a leading researcher in medicinal plant biology, with expertise in plant stress adaptation and bioactive compound biosynthesis. His contributions to plant sciences and phytochemistry continue to advance our understanding of medicinal herbs, making a significant impact on the field of traditional Chinese medicine and agricultural biotechnology.

Yinfeng Chen | Medicine | Women Researcher Award

Published on by Forensic Scientist

Ms. Yinfeng Chen | Medicine | Women Researcher Award

Attending physician | Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University | China

Dr. Yinfeng Chen is an attending physician at the Department of Nephrology, Hangzhou TCM Hospital, affiliated with Zhejiang Chinese Medical University. With over a decade of experience in clinical nephropathy, Dr. Chen has become a recognized expert in the field. She has actively contributed to various academic endeavors and plans to further her research at the Clinical Research Institute of China-Japan Friendship Hospital in 2024. Her expertise lies in kidney diseases, and she is dedicated to providing innovative treatments to improve patient outcomes.

Profile🔍

Scopus

Strengths for the Awards

  • Solid Academic and Professional Background: Yinfeng holds a postgraduate degree in clinical nephropathy from Zhejiang Chinese Medicine University and has 10 years of clinical experience. This provides a solid foundation for her work in the nephrology field.
  • Research Contributions: She has conducted significant research on chronic kidney disease and its correlation with conditions like stroke, diabetic kidney disease, FSGS, and chronic kidney failure. Her work contributes directly to improving patient outcomes and advancing the field of nephrology.
  • Clinical Application and Innovation: Her commitment to providing personalized treatment plans based on individual conditions demonstrates a practical approach to her research, enhancing the impact of her findings on real-world patient care.
  • Active Participation in Academic Activities: She is engaged in further research at the Clinical Research Institute of China-Japan Friendship Hospital, highlighting her dedication to continuous professional development and collaboration.
  • Published Research: Her research has been published in reputable journals (doi: 10.1080/0886022X.2025.2452219), contributing to the academic discourse in the nephrology field.
  • Yinfeng Chen has demonstrated considerable strength in her clinical and research endeavors, particularly in the area of nephrology. Her dedication to improving patient care and advancing the understanding of kidney diseases makes her a strong candidate for the “Women Researcher Award.” With further contributions in publications, patents, or leadership roles in academic organizations, her profile could become even more competitive.

Education 📚

Dr. Chen graduated from Zhejiang Chinese Medicine University with a postgraduate degree in clinical nephropathy. She has since accumulated substantial clinical experience, working in the nephrology department for over 10 years. Her academic journey has continuously been complemented by active participation in academic and research activities.

Experience💼

As an attending physician in nephrology, Dr. Yinfeng Chen has developed tailored treatment plans for patients, particularly in chronic kidney disease (CKD) and diabetic kidney disease. Her decade-long clinical experience has been enriched through various collaborations, including her upcoming research at the Clinical Research Institute of China-Japan Friendship Hospital.

Research Interest On Medicine 🔬

Dr. Chen’s research interests primarily focus on kidney diseases, including chronic kidney disease, stroke, diabetic kidney disease, and FSGS (focal segmental glomerulosclerosis). She has been exploring the correlation between chronic kidney disease and stroke, among other critical issues in nephrology, with a commitment to developing innovative therapies for better patient survival and treatment outcomes.

Awards🏆

Dr. Yinfeng Chen has been nominated for the prestigious “Women Researcher Award,” a recognition of her significant contributions to nephrology and medical research. Her dedication to enhancing kidney disease treatments through her research and clinical expertise makes her an ideal candidate for this award.

Publications📖

Dr. Chen has published several studies in prominent journals. One of her recent articles, titled “Correlation Between Chronic Kidney Disease and Stroke,” was published in the International Journal of Nephrology and Renovascular Disease in 2025. The article can be accessed here. Her work is also cited by numerous other research studies.

Conclusion🌱

With a proven track record in clinical nephrology and an unwavering commitment to advancing kidney disease research, Dr. Yinfeng Chen continues to make significant strides in the field. Her upcoming work and future endeavors promise to further improve kidney disease management and treatment.